Suven Life Sciences' Ropanicant Shows Positive Phase 2a Results for Major Depressive Disorder
核心洞察
Suven Life Sciences announced positive results from its Phase 2a proof-of-concept study of Ropanicant (SUVN-911) in patients with moderate to severe Major Depressive Disorder (搜索) (MDD (搜索)).
Ropanicant, an α4β2 nicotinic acetylcholine receptor (搜索) (nAChR (搜索)) antagonist, demonstrated promising safety and efficacy outcomes in the open-label Phase 2a study.
Suven plans to advance Ropanicant into a double-blind, placebo-controlled Phase 2b clinical study in MDD (搜索) patients, anticipated to start in early 2025.
Suven Life Sciences Ltd. has announced positive results from its Phase 2a proof-of-concept study evaluating Ropanicant (SUVN-911) for the treatment of moderate to severe Major Depressive Disorder (搜索) (MDD (搜索)). The company plans to present these findings at the Neuroscience 2024 conference in Chicago, Illinois.
Ropanicant (SUVN-911) is a selective α4β2 nicotinic acetylcholine receptor (搜索) (nAChR (搜索)) antagonist. The Phase 2a study evaluated the safety and efficacy of Ropanicant in participants with moderate to severe MDD (搜索). While specific data from the Phase 2a trial were not detailed in the announcement, the company stated the results were positive, paving the way for further clinical development.
Planned Phase 2b Trial
Based on the Phase 2a results, Suven intends to initiate a double-blind, placebo-controlled Phase 2b clinical study of Ropanicant in MDD (搜索) patients. The Phase 2b trial is anticipated to begin in early 2025. This study will provide more definitive data on the efficacy and safety of Ropanicant compared to placebo.
Suven's Neuroscience 2024 Presentations
In addition to Ropanicant, Suven Life Sciences will present data on other clinical and preclinical assets at Neuroscience 2024, including:
- Samelisant (SUVN-G3031): Phase 2 proof-of-concept study results in patients with narcolepsy.
- Masupirdine (SUVN-502): Rationale and study design for the Phase 3 clinical development program for agitation in patients with dementia of Alzheimer’s type.
- SUVN-2206043: A dual 5-HT1A and 5-HT2A receptor ligand showing antipsychotic and antidepressant-like effects in animal models.
- SUVN-L3307032: A positive allosteric modulator (PAM) at the muscarinic M4 receptor for the treatment of psychotic symptoms.
Suven's Clinical Pipeline
Suven currently has seven clinical-stage assets across various therapeutic areas. These include Masupirdine (SUVN-502) for agitation in Alzheimer's disease (搜索) (Phase 3), Samelisant (SUVN-G3031) for excessive daytime sleepiness in narcolepsy (Phase 2 completed, Phase 3 planning), Ropanicant (SUVN-911) for MDD (搜索) (Phase 2a completed, Phase 2b planning), Usmarapride (SUVN-D4010) for cognitive disorders (Phase 2 planning), and SUVN-I6107 for cognitive disorders (Phase 1 initiated), along with two other compounds in early clinical development. The company also has six projects in the research pipeline.